von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
von Willebrand Disease (vWD) Market Report Overview
The von Willebrand Disease (vWD) market size in the three major markets (3MM) (US, Germany, and UK) was $892 million in 2022. The vWD market will register a CAGR of more than 8% from 2022 to 2032. The vWD market research report offers an overview of vWD, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the vWD therapeutics market.
vWD Market Outlook 2022-2032 ($ Million)
Buy the Full Report to Know More About vWD Market Forecast, Download a Free Sample Report
von Willebrand Disease (vWD) is the most inherited blood-clotting disorder. It arises from a deficiency in the quality or quantity of von Willebrand factor (vWF), a multimeric protein required for platelet adhesion. There are three types of hereditary vWD—type 1, type 2, and type 3—of which type 2 contains various subtypes (2A, 2B, 2M, and 2N).
Market Size (2022) | $892 million |
CAGR (2022-2032) | >8% |
Key Countries (3MM) | · The US
· UK · Germany |
Key Drugs | · Koate DVI
· Wilfactin · Vonvendi · Desmopressin Acetate · Immunate · Wilate |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
vWD Market Dynamics
- The vWD market is expected to have two novel entrants across the forecast period. These include vWF recombinant for pediatric use and BT-200, an RNA oligonucleotide targeting type 2 vWD. These novel therapies will provide significant opportunities to address the need for long-term, efficacious therapies.
- The entrance of RNA oligonucleotide and vWF recombinant for children will likely increase the treatment options for more challenging and severe types of vWD. This will increase the vWD market size as a greater number of patients will have access to treatment.
vWD Market Segmentation by Country
The key countries in the vWD market are the US, UK, and Germany. In 2022, the US dominated the total vWD market in the 3MM occupying over 80% of the market share. The US’s market dominance is due to the higher price of pharmaceuticals in the US and the high diagnosed prevalence of vWD in the country compared to the other major markets.
vWD Market Analysis by Country, 2022 (%)
Buy the Full Report for Country-Wise Insights on the vWD Market, Download a Free Sample Report
vWD Market Segmentation by Drugs
The key drugs in the vWD market are Koate DVI, Wilfactin, Vonvendi, Desmopressin Acetate, Immunate, Wilate, Fanhdi, Alphanate, and Voncento among others. In 2022, Vonvendi accounted for the highest sales. Vonvendi is a vWF recombinant therapy that directly addresses the underlying vWF deficiency causing the disease. This drug development is currently in Phase III in the US and pre-registration in the EU.
vWD Market Analysis by Drugs, 2022 (%)
Buy the Full Report for Drug-Wise Insights on the vWD Market, Download a Free Sample Report
Segments Covered in this Report
vWD Country Outlook ($ Million, 2022-2032)
- The US
- The UK
- Germany
vWD Drugs Outlook (%, 2022-2032)
- Koate DVI
- Wilfactin
- Vonvendi
- Desmopressin Acetate
- Immunate
- Wilate
Scope
- Annualized vWD therapeutics market revenue in 3MM (the US, Germany, and the UK), the annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032 covering three-time points: base year, 5-year, and 10-year.
- Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for vWD treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 3MM vWD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
Report deliverables include a Pdf report and Excel-based forecast model
Forecast includes three countries: US, Germany, and the UK
Forecasts cover three time points: base year, 5-year, and 10-year
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the vWD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the vWD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
LFB SA
Takeda
Octapharma
Grifols SA
CSL Ltd
CSL Behring LLC
Bio Products Laboratory Ltd
Ferring International Center SA
Sun Pharmaceutical Industries
Dr. Reddy's Laboratories
United Biomedical/Athenax Inc.
Teva Pharmaceutical Industries Ltd
Table of Contents
Frequently asked questions
-
What was the von Willebrand Disease (vWD) market size in 2022?
The von Willebrand Disease (vWD) market size in the three major markets (3MM) (US, Germany, and UK) was $892 million in 2022.
-
What will be the vWD market CAGR during 2022-2032?
The vWD market will register a CAGR of more than 8% from 2022 to 2032 in the three major markets (3MM).
-
Which is the leading country in the 3MM in the vWD market?
In 2022, the US dominated the total vWD market in the 3MM occupying over 80% of the market share.
-
Which is the leading drug brand in the vWD market?
In 2022, Vonvendi accounted for the highest sales.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Von Willebrand Disease (vWD) reports

